Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease

Though Abl inhibitors are often successful therapies for the initial stages of chronic myelogenous leukemia (CML), refractory cases highlight the need for novel molecular insights. We demonstrate that mice deficient in the enzyme 12/15-lipoxygenase (12/15-LO) develop a myeloproliferative disorder (M...

Descripción completa

Detalles Bibliográficos
Autores principales: Middleton, Melissa Kristine, Zukas, Alicia Marie, Rubinstein, Tanya, Jacob, Michele, Zhu, Peijuan, Zhao, Liang, Blair, Ian, Puré, Ellen
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2006
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118138/
https://www.ncbi.nlm.nih.gov/pubmed/17043146
http://dx.doi.org/10.1084/jem.20061444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118138/
https://www.ncbi.nlm.nih.gov/pubmed/17043146
http://dx.doi.org/10.1084/jem.20061444

Ejemplares similares